Cooper, A. J., Herzberg, B., Parma, M., Wang, K., Alder, L., Weber, U. M., … Zhang, B. (2025). Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer. JCO Precis Oncol, 9, e2500538. https://doi.org/10.1200/PO-25-00538

Cooper, Alissa J., Benjamin Herzberg, Mitchell Parma, Kaiwen Wang, Laura Alder, Urs M. Weber, Tejas Patil, et al. “Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer.” JCO Precis Oncol 9 (October 2025): e2500538. https://doi.org/10.1200/PO-25-00538.

Cooper AJ, Herzberg B, Parma M, Wang K, Alder L, Weber UM, et al. Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer. JCO Precis Oncol. 2025 Oct;9:e2500538.

Cooper, Alissa J., et al. “Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer.” JCO Precis Oncol, vol. 9, Oct. 2025, p. e2500538. Pubmed, doi:10.1200/PO-25-00538.

Cooper AJ, Herzberg B, Parma M, Wang K, Alder L, Weber UM, Patil T, Joshi U, Puri S, Saqi A, Clark P, Gay CM, Cascone T, Singhi EK, Blumenschein G, Skoulidis F, Tu J, Stinchcombe TE, Rudin CM, Shu CA, Byers LA, Yu H, Zhang B. Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR-Mutant Transformed Small Cell Lung Cancer. JCO Precis Oncol. 2025 Oct;9:e2500538.